ACRI - Phase 1
Anaheim, California, 92801, United States
NCT Number: NCT01477411
The purpose of this study is to determine if Digoxin is affected by PA21.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Phase 1
Anaheim, California, 92801, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The maximum dose of PA21 will be 15.0 g/day.
The maximum dosage of Digoxin will be 0.5 mg/day
Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post digoxin dose on Days 0, 11, 22
Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours
Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post Digoxin dose on Days 0, 11, 22
Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time
Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post Digoxin dose on days 0, 11, 22
Vifor Pharma
Industry
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05558150
Drug Interaction Potentiation
Seoul, South Korea
View Trial DetailsNCT05237297
Drug Interaction Potentiation
Seoul, South Korea
View Trial DetailsNCT03123640
Behavior, Chemically-Induced Disorders
Oslo, Norway
View Trial DetailsNCT03493698
Drug Interaction Potentiation
Groningen, Netherlands
View Trial Details